Novel agents for metastatic hormone-sensitive prostate cancer - a practice guide for urologists

BJU Int. 2020 Mar;125(3):342-345. doi: 10.1111/bju.14936. Epub 2019 Nov 15.

Isaac A Thangasamy^{1

2}, Edmond M Kwan^{3

4}, Jiasian Teh¹, Niranjan Sathianathen¹, Omar Alghazo¹, Shankar Siva^{5

6}, Arun Azad^{4

6}, Declan G Murphy^{1

6}

¹ Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
² Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
³ Department of Medicine, School of Clinical Sciences, Monash University, Parkville, Victoria, Australia.
⁴ Department of Medical Oncology, Monash Health, Melbourne, Victoria, Australia.
⁵ Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁶ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.

No abstract available

Keywords: PCSM; PostateCancer; androgen axis-targeted therapies; chemotherapy; hormone sensitive; metastatic; prostate cancer.

Publication types